Physicians’ Education Resource® Presents “Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know”

This live symposium will be held adjunct to the 2019 American College of Physicians Internal Medicine Meeting

March 25, 2019 19:39 UTC

This live symposium will be held adjunct to the 2019 American College of Physicians Internal Medicine Meeting

CRANBURY, N.J.--(BUSINESS WIRE)-- Physicians’ Education Resource® (PER®), a worldwide leader in continuing medical education (CME), will conduct a live CME-accredited activity, “Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know,” as a satellite symposium adjunct to the 2019 American College of Physicians Internal Medicine Meeting. The symposium will take place Wednesday, April 10, from 7 to 9 p.m. at the Philadelphia Marriott Downtown and will be chaired by James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA, clinical assistant professor of medicine, NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease and director, Bellevue Hospital Lipid Clinic.

“Although many doctors prescribe statins to help lower cholesterol levels in patients, a large portion of these patients remain at residual cardiovascular disease risk,” said Phil Talamo, president of PER®. “This program will explore the latest cholesterol-lowering national guidelines and evidence for non-statin options for patients who are not reaching lipid-lowering goals.”

In this engaging, interactive, case-based symposium, a panel of renowned experts in dyslipidemia management will review the latest clinical trial data on PCSK9 inhibitors and provide insights into the most challenging lipid-lowering scenarios for managing patients with CVD. Those who attend this symposium will hear expert interpretation of the latest cholesterol-lowering guidelines, receive guidance on issues of statin intolerance and severe hypercholesterolemia, learn evidence-based strategies for management of dyslipidemia with non-statin therapies, and be updated on indications for PCSK9 inhibitors and real-world experience, as well as have an opportunity to network with peers.

This live activity is accredited by the Accreditation Council for Continuing Medical Education for 2.0 AMA PRA Category 1 Credits™ for physicians. For more information and to register, click here.

About Physicians’ Education Resource® (PER®)

Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While continuing to expand into topics outside of oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates, Inc., family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.

Contacts

PER® Media Contacts
Alexandra Ventura, 609-716-7777, ext. 121
aventura@mjhassoc.com

John Patricolo, 609-325-4630
jpatricolo@mjhassoc.com

Source: Physicians’ Education Resource

MORE ON THIS TOPIC